Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00188084
Status:
UNKNOWN
Last Update Posted:
2005-10-28
First Post:
2005-09-12
Brief Title:
Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia
Sponsor:
University Hospital Angers
Organization:
University Hospital Angers
Study Overview
Official Title:
Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia DNA Index Percentage of Cells in S-Phase CD45 Fluorescence Index and Protein P16 Prognostic Study in Patients Enrolled in a Multicentric Trial
Status:
UNKNOWN
Status Verified Date:
2005-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification including cytogenetics We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients
1 A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy percentage of cells in S-phase CD45 fluorescence index
2 The proteine P16 metabolic way involved in cell cycle regulation will be studied by Western Blot analysis
The comparison between these parameters and main haematological data will be followed by a prognostic analysis based on blast corticosensibility in vivo chimiosensibility complete remission and survival
Combination of the studied parameters will allow to appreciate a clonal diversity This will help to predict at diagnosis high probability of resistance to treatment
1 A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy percentage of cells in S-phase CD45 fluorescence index
2 The proteine P16 metabolic way involved in cell cycle regulation will be studied by Western Blot analysis
The comparison between these parameters and main haematological data will be followed by a prognostic analysis based on blast corticosensibility in vivo chimiosensibility complete remission and survival
Combination of the studied parameters will allow to appreciate a clonal diversity This will help to predict at diagnosis high probability of resistance to treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GOELAMS 271-003 | None | None | None |